INDP Indaptus Corp: Long-Term Debt to Capital Coefficient

This chart of the market price for Indaptus Therapeutics (INDP) reflects the performance of a company developing methods to combat solid tumors through immune stimulation, with the indicator standing at 0.00. The business relies on the bold use of inactivated bacteria for cancer therapy; however, the project's sustainability is constrained by a shortage of funds and drug toxicity risks during the early stages of clinical trials.

Defensive assets are selected based on the criterion of minimal debt load. Indaptus Therapeutics (INDP) aligns with this approach by investing in the development of bacterial drugs for the therapy of solid tumors. The metric compares liabilities with a maturity of over one year against total equity. By analyzing the ratio of long-term loans to equity, an investor assesses the degree of financial leverage. A decrease in this indicator confirms the stability of the funding structure for innovations.